Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $87.46.

RARE has been the topic of several recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. TD Cowen boosted their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Canaccord Genuity Group restated a “buy” rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. reduced their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research note on Thursday, November 21st.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 8,273 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the sale, the chief executive officer now owns 2,195,712 shares in the company, valued at $109,785,600. This represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently modified their holdings of the company. True Wealth Design LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter valued at approximately $43,000. nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $33,000. UMB Bank n.a. increased its position in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 352 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $56,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at about $83,000. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 2.4 %

RARE opened at $45.78 on Friday. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37. The company has a fifty day moving average of $50.47 and a 200-day moving average of $49.15. The stock has a market cap of $4.23 billion, a PE ratio of -7.08 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business’s revenue was up 42.3% compared to the same quarter last year. During the same period last year, the business posted ($2.23) EPS. Sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -6.2 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.